NCT00538096 - A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

May 31, 2010

Conditions

Lymphoma, B-CellLymphoma, Non-Hodgkin

Interventions

DRUG

MEDI-538

1 of 3 target doses of MEDI-538 (5,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.

DRUG

MEDI-538

1 of 3 target doses of MEDI-538 (10,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.

DRUG

MEDI-538

1 of 3 target doses of MEDI-538 (15,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.